TGFBR2 and cancer: Eight targets (EP300, CASP3, CASP8, CHEK2, CREBBP, NOTCH1, PPARG, and TGFBR2) were TSGs (Figure 4, gray text), suggesting that antagonizing these molecules might increase the susceptibility to cancer in healthy individuals.